FDA’s Deadline To Update “Off Label” Policy
This article was originally published in RPM Report
A new provision in the “21st Century Cures” bill would set a deadline for FDA to issue update its policy on off-label information dissemination. That deadline is likely to come in late 2017 – and it probably behooves FDA to act by then regardless of what happens in the Cures legislation.
You may also be interested in...
Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.
Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.
Formal MACPAC proposal to US Congress to consider enhanced rebates for drugs approved via the Accelerated Approval pathway could have a long shelf life in the context of debates over drug pricing – and over FDA regulatory reforms.